Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K63-Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6

Arthritis and Rheumatology

Volumn 68, Issue 2, 2016, Pages 347-358

  Singh, Anil K ^a   Umar, Sadiq ^a   Riegsecker, Sharayah ^b   Chourasia, Mukesh ^c   Ahmed, Salahuddin ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c National Institute of Pharmaceutical Education and Research (NIPER)   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; ANTIINFLAMMATORY AGENT; CATECHIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; LYSINE; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEASOME;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; MOLECULAR DOCKING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT; UBIQUITINATION; ANALOGS AND DERIVATIVES; ANIMAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL ARTHRITIS; FIBROBLAST; LEWIS RAT; METABOLISM; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CATECHIN; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; HUMANS; IMMUNOPRECIPITATION; IN VITRO TECHNIQUES; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LYSINE; MAP KINASE KINASE KINASES; MOLECULAR DOCKING SIMULATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, INBRED LEW; SYNOVIAL MEMBRANE; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITINATION;

EID: 84956810331     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39447     Document Type: Article

References (52)

1. Bottini N, Firestein GS., Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2013; 9: 24-33.
2. Clark JD, Flanagan ME, Telliez JB., Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014; 57: 5023-38.
3. Fox DA., Kinase inhibition: a new approach to the treatment of rheumatoid arthritis. N Engl J Med 2012; 367: 565-7.
4. Meier FM, McInnes IB., Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Clin Res Rheumatol 2014; 28: 605-24.
5. Sakurai H., Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012; 33: 522-30.
6. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ., TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412: 346-51.
7. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al., Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995; 270: 2008-11.
8. Dinarello CA, van der Meer JW., Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 2013; 25: 469-84.
9. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al., Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000; 191: 313-20.
10. Salliot C, Dougados M, Gossec L., Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
11. Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, et al., Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum 2004; 50: 725-8.
12. Bahia MS, Kaur M, Silakari P, Silakari O., Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cell Signal 2015; 27: 1039-55.
13. Cui W, Xiao N, Xiao H, Zhou H, Yu M, Gu J, et al., β-TrCP-mediated IRAK1 degradation releases TAK1-TRAF6 from the membrane to the cytosol for TAK1-dependent NF-κB activation. Mol Cell Biol 2012; 32: 3990-4000.
14. Zhou H, Yu M, Fukuda K, Im J, Yao P, Cui W, et al., IRAK-M mediates Toll-like receptor/IL-1R-induced NFκB activation and cytokine production. EMBO J 2013; 32: 583-96.
15. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, et al., The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008; 10: 1199-207.
16. Chen ZJ., Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246: 95-106.
17. Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, et al., Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci U S A 2008; 105: 14692-7.
18. Ahmed S, Pakozdi A, Koch AE., Regulation of interleukin-1β-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2006; 54: 2393-401.
19. Ahmed S, Silverman MD, Marotte H, Kwan K, Matuszczak N, Koch AE., Down-regulation of myeloid cell leukemia 1 by epigallocatechin-3-gallate sensitizes rheumatoid arthritis synovial fibroblasts to tumor necrosis factor α-induced apoptosis. Arthritis Rheum 2009; 60: 1282-93.
20. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE., Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219-44.
21. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K., The kinase TAK1 can activate the NIK-I κB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999; 398: 252-6.
22. Knop J, Martin MU., Effects of IL-1 receptor-associated kinase (IRAK) expression on IL-1 signaling are independent of its kinase activity. FEBS Lett 1999; 448: 81-5.
23. Li X, Commane M, Burns C, Vithalani K, Cao Z, Stark GR., Mutant cells that do not respond to interleukin-1 (IL-1) reveal a novel role for IL-1 receptor-associated kinase. Mol Cell Biol 1999; 19: 4643-52.
24. Maschera B, Ray K, Burns K, Volpe F., Overexpression of an enzymically inactive interleukin-1-receptor-associated kinase activates nuclear factor-κ B Biochem J 1999; 339: 227-31.
25. Ajibade AA, Wang HY, Wang RF., Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol 2013; 34: 307-16.
26. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H., Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 2005; 280: 7359-68.
27. Yu Y, Ge N, Xie M, Sun W, Burlingame S, Pass AK, et al., Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFκB and AP-1 activation as well as IL-6 gene expression. J Biol Chem 2008; 283: 24497-505.
28. Kilty I, Jones LH., TAK1 selective inhibition: state of the art and future opportunities. Future Med Chem 2015; 7: 23-33.
29. Adhikari A, Xu M, Chen ZJ., Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007; 26: 3214-26.
30. Komander D, Clague MJ, Urbe S., Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-63.
31. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG., Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of IκB kinase activation. J Biol Chem 2007; 282: 4102-12.
32. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, et al., Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS Chem Biol 2013; 8: 643-50.
33. Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, et al., Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-9.
34. Cushing L, Stochaj W, Siegel M, Czerwinski R, Dower K, Wright Q, et al., Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner. J Biol Chem 2014; 289: 10865-75.
35. Song KW, Talamas FX, Suttmann RT, Olson PS, Barnett JW, Lee SW, et al., The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Mol Immunol 2009; 46: 1458-66.
36. Tieri P, Zhou X, Zhu L, Nardini C., Multi-omic landscape of rheumatoid arthritis: re-evaluation of drug adverse effects. Front Cell Dev Biol 2014; 2: 59.
37. Cao Y, Jiao Y, Wang L, Huang Y, Postlethwaite A, Stuart J, et al., Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts: from the point of view of mouse genomics. Int Immunopharmacol 2012; 13: 28-36.
38. Hammaker DR, Boyle DL, Inoue T, Firestein GS., Regulation of the JNK pathway by TGF-β activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 2007; 9: R57.
39. Courties G, Seiffart V, Presumey J, Escriou V, Scherman D, Zwerina J, et al., In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010; 116: 3505-16.
40. Dai L, Aye Thu C, Liu XY, Xi J, Cheung PC., TAK1, more than just innate immunity. IUBMB Life 2012; 64: 825-34.
41. Chen ZJ., Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005; 7: 758-65.
42. Nathan JA, Kim HT, Ting L, Gygi SP, Goldberg AL., Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J 2013; 32: 552-65.
43. Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM., Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004; 308: 767-73.
44. Hafeez BB, Ahmed S, Wang N, Gupta S, Zhang A, Haqqi TM., Green tea polyphenols-induced apoptosis in human osteosarcoma SAOS-2 cells involves a caspase-dependent mechanism with downregulation of nuclear factor-κB. Toxicol Appl Pharmacol 2006; 216: 11-9.
45. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM., Epigallocatechin-3-gallate inhibits interleukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor κB activation by degradation of the inhibitor of nuclear factor κB. Arthritis Rheum 2002; 46: 2079-86.
46. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al., Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-61.
47. Wu H, Arron JR., TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays 2003; 25: 1096-105.
48. Furst DE., The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39: 327-46.
49. Khanna D, McMahon M, Furst DE., Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27: 307-24.
50. Chang SK, Noss EH, Chen M, Gu Z, Townsend K, Grenha R, et al., Cadherin-11 regulates fibroblast inflammation. Proc Natl Acad Sci U S A 2011; 108: 8402-7.
51. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al., Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006-10.
52. Bartok B, Firestein GS., Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.